{"id":"W4321077653","doi":"10.1038/s41591-022-02200-8","title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute on Alcohol Abuse and Alcoholism; Novartis Pharma; AstraZeneca; Allergan; Regeneron Pharmaceuticals; National Institutes of Health; Novo Nordisk; Virginia Commonwealth University; Eisai; Intercept Pharmaceuticals; Mallinckrodt Pharmaceuticals; Ionis Pharmaceuticals; Genentech; Boston Scientific Corporation; Valeant Pharmaceuticals International; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Amgen; NGM Biopharmaceuticals; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Placebo; Tolerability; Medicine; Internal medicine; Nonalcoholic steatohepatitis; Gastroenterology; Adverse effect; Randomized controlled trial; Farnesoid X receptor; Nonalcoholic fatty liver disease; Fatty liver; Pathology; Chemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001154731,0.0004101017,0.002255525,0.0004187462,0.0001502573,0.00001754841,0.0001521939,0.0003531355,0.0004518558],"category_scores_gemma":[0.00178827,0.0002454813,0.0006264102,0.0004358226,0.0002180392,0.000108503,0.00002572946,0.0004270999,0.00006703446],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001214769,"about_ca_system_score_gemma":0.0002279783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006726779,"about_ca_topic_score_gemma":0.0000210674,"domain_scores_codex":[0.9971703,0.0002502822,0.0007242801,0.0006037262,0.0007595895,0.0004918341],"domain_scores_gemma":[0.9966022,0.00180327,0.0002349975,0.0004972506,0.0003192292,0.0005430003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9654475,0.001548114,0.0001597698,0.00008025171,0.001477931,0.0002524036,0.0003007217,0.00000133519,0.00008442577,0.002380965,0.01887657,0.009389997],"study_design_scores_gemma":[0.978192,0.007644618,0.0006129858,0.0003327323,0.004017265,0.00001609789,0.0001790686,0.002718708,0.0001908423,0.0004534789,0.005426314,0.0002158826],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.959633,0.005907365,0.0001716024,0.01008483,0.002103503,0.01847533,0.0002475194,0.0004537376,0.002923123],"genre_scores_gemma":[0.9842253,0.0006958153,0.0002748159,0.002583904,0.003592266,0.005425053,0.001271483,0.00006977725,0.001861596],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02459231,"threshold_uncertainty_score":0.9999998,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03241289666123781,"score_gpt":0.3781655163415215,"score_spread":0.3457526196802837,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}